Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans

The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013

(2016) G. Janow et al.   JOURNAL OF RHEUMATOLOGY

Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000-2013

(2016) Jens Klotsche et al.   Arthritis & Rheumatology

Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan

(2015) Shumpei Yokota et al.   ANNALS OF THE RHEUMATIC DISEASES

2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among C

(2015) Sarah Ringold et al.   ARTHRITIS AND RHEUMATISM

Adding Canakinumab to the Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Systemic Juvenile Idiopathic Arthritis: Comment on the Article by DeWitt et al

(2014) Yukiko Kimura et al.   ARTHRITIS CARE & RESEARCH

Review: Is There a Window of Opportunity for Treatment of Systemic Juvenile Idiopathic Arthritis?

(2014) Peter A. Nigrovic   Arthritis & Rheumatology

Comparative Effectiveness Research: A Report From the Institute of Medicine

(2013) Harold C. Sox   ANNALS OF INTERNAL MEDICINE

Effectiveness of First-Line Treatment With Recombinant Interleukin-1 Receptor Antagonist in Steroid-Naive Patients With New-Onset Systemic Juvenile Idiopathic Arthritis: Results of a Prospective Cohort Study

(2013) Sebastiaan J. Vastert et al.   Arthritis & Rheumatology

Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

(2012) Nicolino Ruperto et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis

(2012) Fabrizio De Benedetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pulmonary Hypertension and Other Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis

(2012) Yukiko Kimura et al.   ARTHRITIS CARE & RESEARCH

Evaluation of Clinical Measures and Different Criteria for Diagnosis of Adult-onset Still's Disease in a Chinese Population

(2011) L. JIANG et al.   JOURNAL OF RHEUMATOLOGY

Juvenile idiopathic arthritis

(2011) Berent Prakken et al.   LANCET

American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis

(2011) Carol A. Wallace et al.   ARTHRITIS CARE & RESEARCH

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

(2011) Timothy Beukelman et al.   ARTHRITIS CARE & RESEARCH

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

(2010) P. Quartier et al.   ANNALS OF THE RHEUMATIC DISEASES

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series

(2010) Peter A. Nigrovic et al.   ARTHRITIS AND RHEUMATISM

A tutorial on pilot studies: the what, why and how

(2010) Lehana Thabane et al.   BMC Medical Research Methodology

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

(2008) Shumpei Yokota et al.   LANCET